Licker Marc, Ellenberger Christoph, Sierra Jorge, Kalangos Afksendiyos, Diaper John, Morel Denis
Department of Anesthesiology, Pharmacology, and Surgical Intensive Care, University Hospital of Geneva, Geneva, Switzerland.
Chest. 2005 Aug;128(2):838-47. doi: 10.1378/chest.128.2.838.
We hypothesized that lowering blood viscosity with acute normovolemic hemodilution (ANH) would confer additional cardioprotection in patients undergoing coronary artery bypass surgery (CABG) with aortic cross-clamping.
In a prospective, randomized controlled trial, we studied the efficacy of ANH in anesthetized patients prior to cardiopulmonary bypass for the prevention of myocardial injuries.
Cardiac surgical center in a university hospital.
Patients scheduled to undergo elective CABG entered the study protocol and were randomly allocated to one of two groups: ANH (n = 43 patients) or standard care management (n = 41 patients). In the ANH group, the whole-blood/colloid exchange was aimed to achieve a hematocrit value of 28%. All patients were managed with standard myocardial preservation techniques including cold-blood cardioplegia and anesthetic preconditioning. The outcome measures included the release of myocardial enzymes (plasma troponin I and creatinine phosphokinase), perioperative hemodynamic changes, need for pharmacologic cardiovascular support, and cardiac complications.
In the hemodilution group, the postoperative release of troponin I (mean peak plasma concentration, 1.4 ng/mL; 95% confidence interval, 1.0 to 1.8) and myocardial fraction of creatine kinase (mean, 29 U/L; 95% confidence interval, 23 to 35) were significantly lower than in the control group (mean, 3.8 ng/mL; 95% confidence interval, 3.2 to 4.5; and 71 U/L; 95% confidence interval, 53 to 89). Requirement for inotropic support was significantly lower in the protocol patients (7 of 41 patients vs 15 of 39 patients), and fewer patients presented with either atrial fibrillation, atrioventricular conduction blockade, or combined disorders (12 of 41 patients vs 26 of 39 patients, p < 0.05).
In addition to conventional myocardial preservation techniques, preoperative ANH achieved further cardiac protection in patients undergoing on-pump myocardial revascularization.
我们假设,通过急性等容血液稀释(ANH)降低血液粘度,将为接受主动脉交叉钳夹冠状动脉搭桥手术(CABG)的患者提供额外的心脏保护。
在一项前瞻性随机对照试验中,我们研究了在体外循环前对麻醉患者进行ANH预防心肌损伤的疗效。
大学医院的心脏外科中心。
计划接受择期CABG的患者进入研究方案,并随机分为两组之一:ANH组(43例患者)或标准护理管理组(41例患者)。在ANH组中,全血/胶体交换旨在使血细胞比容值达到28%。所有患者均采用标准的心肌保护技术,包括冷血心脏停搏液和麻醉预处理。观察指标包括心肌酶(血浆肌钙蛋白I和肌酸磷酸激酶)的释放、围手术期血流动力学变化、药物心血管支持的需求以及心脏并发症。
在血液稀释组中,术后肌钙蛋白I的释放(平均血浆峰值浓度,1.4 ng/mL;95%置信区间,1.0至1.8)和肌酸激酶心肌部分(平均,29 U/L;95%置信区间,23至35)显著低于对照组(平均,3.8 ng/mL;95%置信区间,3.2至4.5;以及71 U/L;95%置信区间,53至89)。方案患者对正性肌力支持的需求显著较低(41例患者中的7例对39例患者中的15例),出现房颤、房室传导阻滞或合并疾病的患者较少(41例患者中的12例对39例患者中的26例,p<0.05)。
除了传统的心肌保护技术外,术前ANH在接受体外循环心肌血运重建的患者中实现了进一步的心脏保护。